Andrzej Jakubowiak to Cost-Benefit Analysis
This is a "connection" page, showing publications Andrzej Jakubowiak has written about Cost-Benefit Analysis.
Connection Strength
1.077
-
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 12; 10(12):1107-1119.
Score: 0.498
-
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016 Nov; 19(11):1061-1074.
Score: 0.450
-
Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma. J Manag Care Spec Pharm. 2018 07; 24(7):711-712.
Score: 0.130